Skip to main content

AS/Spondyloarthritis

COVID,vaccinate,injection,green

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Jan 13, 2022

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.



Rheumatic and autoimmune patients were not

Read Article
ICYMI: Study of biologic/ts DMARD switching in 8,398 axial spondyloarthritis pts from 5 Nordic registries showed a low rate of multiple switches (refractory?) over 3 years; ≥3 DMARDs (8%), ≥4 (3%) & ≥ 5 (1%); more w/ women, comorbiditiy & psoriasis https://t.co/tc5D3Bwnnj

Dr. John Cush @RheumNow( View Tweet )

Jan 09, 2022
2021,year

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/7q5sMQuIHj https://t.co/ksCCvzdxka
Dr. John Cush @RheumNow( View Tweet )
Jan 05, 2022
Study of biologic/ts DMARD switching in 8,398 axial spondyloarthritis pts from 5 Nordic registries showed a low rate of multiple switches (refractory?) over 3 years; ≥3 DMARDs (8%), ≥4 (3%) & ≥ 5 (1%); more w/ women, comorbiditiy & psoriasis https://t.co/ZQDvl6AaZz

Dr. John Cush @RheumNow( View Tweet )

Jan 03, 2022
FDA.Safety.jpg

Best of 2021: FDA Puts Boxed Warnings on JAK Inhibitors

Dec 30, 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before

Read Article
RheumNow Podcast square

Best of 2021: Tofacitinib Safety Concerns

Dec 29, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
COVID vaccine vials

Best of 2021: Israel provides COVID vaccine answers for rheumatic disease patients

Dec 28, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has

Read Article
Registration now open for RheumNow Live! Join us March 19-20 in Irving, TX or virtually!https://t.co/py6Gp8sPh8

Dr. John Cush @RheumNow( View Tweet )

Dec 24, 2021
Download your RheumaKnowledgy Card https://t.co/GauMzCH5lB https://t.co/CrS7r6RAoc

Dr. John Cush @RheumNow( View Tweet )

Dec 22, 2021
RheumNow Podcast square

Indications Awaiting (12.17.21)

Dec 17, 2021

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory

Read Article
Cancer,cells

Certain Cancers Increased with Autoimmune Diseases

Dec 16, 2021

Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer,

Read Article
FDA.approved.jpg

Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis

MedPage Today
Dec 15, 2021

The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced on Tuesday.



Tofacitinib is

Read Article
ICYMI: TNF inhibitors and radiographic progression in axSpA A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with (ax-Spa, whether they are diagnosed with -axSpa or nr-axSpA disease.https://t.co/H0Fr54PwOP https://t.co/tFZJUr1j4B
Dr. John Cush @RheumNow( View Tweet )
Dec 12, 2021
ICYMI:CDC and the ICD-10 Coordination and Maintenance Committee has assigned a diagnostic code for non-radiographic axial spondyloarthritis (nr-axSpA) == M45.A

Dr. John Cush @RheumNow( View Tweet )

Dec 12, 2021
RheumNow Podcast square

T2T Debate - A Prologue with Dr. Marty Bergman

Dec 10, 2021

Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology.



Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022.



You can register and learn more about the meeting at:

Read Article
switch.jpg

Monitoring Infliximab Drug Levels Improves Efficacy

Dec 08, 2021

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?



The NOR-DRUM trials (A and B) are the first randomized trials to assess the impact of proactive therapeutic drug monitoring of infliximab in the treatment of

Read Article
Spondyloarthritis Panel Discussion: ACR21 Meetinghttps://t.co/lR6zPHKpOo https://t.co/JGsloJUD2t
Dr. John Cush @RheumNow( View Tweet )
Dec 07, 2021
FDA.Safety.jpg

FDA Puts Boxed Warnings on JAK Inhibitors

Dec 06, 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before

Read Article
ICYMI: New Insights into Uveitis in Spondyloarthritis Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). Read more on RheumNow.https://t.co/JF7TtE8SVJ https://t.co/Sw2b1WX5ko
Dr. John Cush @RheumNow( View Tweet )
Dec 05, 2021
Spondyloarthritis Panel Discussion: ACR21 Meeting Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood discuss abstracts #0562, #1919, #0907, #0364 and #0919 @synovialjoints @doctorRBC @uptoTate @RHEUMarampa @AkhilSoodMD https://t.co/g0ARcP26wt https://t.co/8Lpwpf6AI1
Dr. John Cush @RheumNow( View Tweet )
Dec 03, 2021
SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
Watch: TNFi in axSpAhttps://t.co/uS01KNDgIH https://t.co/eb0W3fBKhq
Dr. John Cush @RheumNow( View Tweet )
Dec 02, 2021
uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

Dec 01, 2021

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis. Being such a prevalent EAM in

Read Article
Pregnancy Outcomes in PsA, SpA, RA: Dr. Rachel Tate ( @uptoTate) reviews abstracts #0369, #1722 and #1730 presented at the ACR21 annual meeting.https://t.co/kUQReWtEdO https://t.co/MZ9Fe1Ms3N
Dr. John Cush @RheumNow( View Tweet )
Nov 30, 2021
×